Processa Pharmaceuticals, Inc.
PCSA · XNASCIK 1533743fmd_1XGBDJ3WHE93ZPW182FYGW77M0制造业 · 医药制剂模板: 标准
覆盖范围: 2012年1月01日 至 2026年6月30日，共 57 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | 0 | – | – | – | – | 0 | 0 | – | – | – |
| 营业成本 | – | – | – | – | – | – | – | – | – | – |
| 毛利润 | 0 | – | – | – | – | – | – | – | – | – |
| 研发费用 | 2 | 1 | 3 | 2 | 3 | 7 | 11 | 6 | 7 | 8 |
| 销售、一般及管理费用 | 0 | 1 | 1 | – | – | – | – | – | – | – |
| 营业费用合计 | 2 | 2 | – | – | – | – | – | – | – | – |
| 营业利润 | (2) | (2) | (5) | (4) | (15) | (12) | (28) | (11) | (12) | (14) |
| 利息费用 | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – | – |
| 利息及投资收益 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 税前利润 | (0) | (2) | (5) | (4) | (15) | (12) | (27) | (11) | (12) | (14) |
| 所得税费用 | – | 0 | (1) | (1) | (1) | (1) | – | – | – | – |
| 持续经营净利润 | (2) | (2) | (4) | (3) | (14) | (11) | – | – | – | – |
| 净利润 | (2) | (2) | (4) | (3) | (14) | (11) | (27) | (11) | (12) | (14) |
| 归属于普通股股东的净利润 | (0) | – | (4) | (4) | (19) | (11) | (27) | (11) | (12) | (14) |